{
    "nctId": "NCT01491295",
    "officialTitle": "Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment",
    "inclusionCriteria": "* HBsAg-positive for more than 6 months (HBeAg-positive or HBeAg-negative).\n* Age \\> 20 y/o.\n* Under lamivudine/adefovir treatment for more than 1 year due to previous lamivudine resistance (LAM-R), current HBV DNA is undetectable (\\< 20 IU/ml) during enrollment.\n* Must have minimum age of 20 Years",
    "exclusionCriteria": "* HCV, HIV, HDV coinfection.\n* Uncontrolled HCC, malignancy or decompensated liver cirrhosis (CTP score \u2265 7).\n* Uremia patients or Creatinine \u2265 2 mg/dl."
}